Smartlab Europe

Alcami Expands Biopharma Storage at Masy BioServices

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...
- Advertisement -

Alcami announced plans to expand its biostorage footprint at Masy BioServices. Joining the company’s existing New England campus is a new 160,000 square-foot facility, purpose-built for cGMP pallet storage space at 15°C to 30°C.

“As the preferred provider of cGMP storage, this expansion adds additional secure and dedicated cGMP space to meet client demand and represents the latest step in our strategic growth initiatives,” commented Patrick Walsh, Alcami Chairman & CEO.

Located in Amherst, N.H., the facility features state-of-the-art infrastructure and systems and will come online in three phases, with the first phase online next month with immediate capacity for over 7,000 pallets. Phase two is targeted to come online in the second half of 2022, which will double the capacity, with the remaining phase under review based on customer needs.

Masy BioServices, acquired by Alcami in December 2021, now operates four cGMP biostorage facilities near Boston, Massachusetts, offering secure and tightly controlled cGMP temperature storage from -135?C to 70?C, including all ICH stability conditions, for various materials including vaccines, biopharmaceuticals, cell banks, tissues, pharmaceutical compounds, and medical devices.

“We continue to expand across all Alcami service offerings and provide our customers reliable solutions for their clinical and commercial programs,” commented Timothy Compton, Chief Business Officer at Alcami.

 

Latest stories

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »